CS Scar Impact on ART Outcomes

Fertility Issues Clinical Trial

Official title:

CS Scar Impact on ART Outcomes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06021886
• Other study ID #: REC/2023/P38
• Status: Recruiting
• Start date: June 15, 2023
• Est. completion date: January 1, 2024

Study information

• Verified date: November 2023
• Source: HealthPlus Fertility Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

CS scar impact on ART outcomes, Retrospective Cohort Study IVF outcome can be affected by the presence of caesarean section scar with or without defect in different ways

Description:

CS scar impact on ART outcomes, Retrospective Cohort Study IVF outcome can be affected by the presence of caesarean section scar with or without defect in different ways; increase difficulty of embryo transfer, presence intrauterine fluid at the time of transfer can affect the chances of embryo implantation and increase the rate of spontaneous miscarriages To compare the success rates and outcomes of pregnancies of frozen embryo transfer for euploid embryos in patients without caesarean section, and who had caesarean section (with or without a NICHE) after euploid embryo transfer. Does CS scar and CS scar defect affect IVF outcome? All women who underwent an embryo transfer with a Euploid embryo between 2015 and 2022, who meet the inclusion criteria will be included in the study.

• Inclusion Criteria: Age 25-40 years old. Euploid embryo transfer. Medically free BMI less tha 30 kg/m2 Hormone therapy preparation for FET.

• Exclusion criteria Previous uterine scar other than cesarean section. Congenital uterine abnormalities Presence of intrauterine lesions e.g., polyp, fibroid, Endometriosis or adenomyosis Hydrosalpinx, Chronic endometritis

• Primary outcome: Clinical pregnancy rate, defined as a pregnancy with a detectable heart rate at 7 weeks of gestation or beyond.

• Secondary outcomes : Early pregnancy complications Ectopic pregnancy or Miscarriage. Caesarean section scar dehiscence or

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 510
• Est. completion date: January 1, 2024
• Est. primary completion date: January 1, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 25 Years to 40 Years

Eligibility

Inclusion Criteria:

• Age 25-40 years old.

Euploid embryo transfer.

Medically free

BMI less tha 30 kg/m2

Hormone therapy preparation for FET.

Exclusion Criteria:

• Exclusion criteria

Previous uterine scar other than cesarean section.

Congenital uterine abnormalities

Presence of intrauterine lesions e.g., polyp, fibroid,

Endometriosis or adenomyosis

Hydrosalpinx, Chronic endometritis

Related Conditions & MeSH terms

• Fertility Issues
• Infertility

Locations

Country	Name	City	State
United Arab Emirates	HealthPlus fertility Centre	Abu Dhabi

Sponsors (1)

Lead Sponsor	Collaborator
HealthPlus Fertility Center

Country where clinical trial is conducted

United Arab Emirates, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CS scar impact on ART outcomes, Retrospective Cohort Study	Clinical pregnancy rate	2015 to 2022,
Secondary	ART outcomes	Early pregnancy complications: Ectopic pregnancy or Miscarriage.; Caesarean section scar dehiscence or rupture.; Presence of intrauterine fluid accumulation at the time of ET.; Endometrial thickness at the time of ET.; Live birth.	2015 to 2022,